Last reviewed · How we verify
Nemonoxacin Malate Sodium Chloride
At a glance
| Generic name | Nemonoxacin Malate Sodium Chloride |
|---|---|
| Sponsor | TaiGen Biotechnology Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Malate Sodium Chloride (PHASE2)
- A Study of Nemonoxacin Malate Sodium Chloride Injection Administered by Intravenous Infusion (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nemonoxacin Malate Sodium Chloride CI brief — competitive landscape report
- Nemonoxacin Malate Sodium Chloride updates RSS · CI watch RSS
- TaiGen Biotechnology Co., Ltd. portfolio CI